Clinical Trial Update: Rifaximin as a Modulator of Microbial Translocation and Immune Activation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rifaximin as a modulator of microbial translocation and immune activation in HIV-1 infection has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2013-11-07